XERIS BIOPHARMA HOLDINGS, INC. Research and Development Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Research and Development Expense of $10.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $10.67M, a 32.45% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $8.78M, a 13.29% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $7.87M, a 29.25% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $7.48M, a 27.09% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for fiscal 2025 was $31.16M, a 21.93% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for fiscal 2024 was $25.56M, a 14.41% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for fiscal 2023 was $22.34M, a 6.56% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. research and development expense for fiscal 2022 was $20.97M, a 16.67% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.67M 10-Q · filed 2026-08-06 | $19.45M 10-Q · filed 2026-08-06 | $27.33M derived: sum of 3 quarters · filed 2026-08-06 | $34.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.78M 10-Q · filed 2026-05-07 | $16.66M derived: sum of 2 quarters · filed 2026-05-07 | $24.14M derived: sum of 3 quarters · filed 2026-05-07 | $32.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.36M derived: sum of 2 quarters · filed 2026-03-02 | $23.41M derived: sum of 3 quarters · filed 2026-08-06 | $31.16M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.48M 10-Q · filed 2025-11-06 | $15.54M derived: sum of 2 quarters · filed 2026-08-06 | $23.29M 10-Q · filed 2025-11-06 | $29.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.05M 10-Q · filed 2026-08-06 | $15.81M 10-Q · filed 2026-08-06 | $21.90M derived: sum of 3 quarters · filed 2026-08-06 | $27.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.75M 10-Q · filed 2026-05-07 | $13.85M derived: sum of 2 quarters · filed 2026-05-07 | $19.73M derived: sum of 3 quarters · filed 2026-05-07 | $25.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.98M derived: sum of 2 quarters · filed 2026-03-02 | $17.74M derived: sum of 3 quarters · filed 2026-03-02 | $25.56M 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.89M 10-Q · filed 2025-11-06 | $11.65M derived: sum of 2 quarters · filed 2025-11-06 | $19.47M 10-Q · filed 2025-11-06 | $25.85M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.76M 10-Q · filed 2025-08-07 | $13.58M 10-Q · filed 2025-08-07 | $19.96M derived: sum of 3 quarters · filed 2026-03-02 | $25.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $7.82M 10-Q · filed 2025-05-08 | $14.20M derived: sum of 2 quarters · filed 2026-03-02 | $19.24M derived: sum of 3 quarters · filed 2026-03-02 | $25.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.42M derived: sum of 2 quarters · filed 2026-03-02 | $17.50M derived: sum of 3 quarters · filed 2026-03-02 | $22.34M 10-K · filed 2026-03-02 |
| 2023-09-30 | $5.03M 10-Q · filed 2024-11-08 | $11.12M derived: sum of 2 quarters · filed 2024-11-08 | $15.96M 10-Q · filed 2024-11-08 | $20.91M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $6.09M 10-Q · filed 2024-08-08 | $10.93M 10-Q · filed 2024-08-08 | $15.88M derived: sum of 3 quarters · filed 2025-03-06 | $21.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $4.84M 10-Q · filed 2024-05-09 | $9.79M derived: sum of 2 quarters · filed 2025-03-06 | $15.84M derived: sum of 3 quarters · filed 2025-03-06 | $19.55M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $11.00M derived: sum of 2 quarters · filed 2025-03-06 | $14.72M derived: sum of 3 quarters · filed 2025-03-06 | $20.97M 10-K · filed 2025-03-06 |
| 2022-09-30 | $6.04M 10-Q · filed 2023-11-09 | $9.76M derived: sum of 2 quarters · filed 2023-11-09 | $16.01M 10-Q · filed 2023-11-09 | $26.09M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $3.72M 10-Q · filed 2023-08-08 | $9.97M 10-Q · filed 2023-08-08 | $20.05M derived: sum of 3 quarters · filed 2024-03-06 | $25.71M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $6.25M 10-Q · filed 2023-05-09 | $16.33M derived: sum of 2 quarters · filed 2024-03-06 | $22.00M derived: sum of 3 quarters · filed 2024-03-06 | $27.38M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $10.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $15.74M derived: sum of 2 quarters · filed 2024-03-06 | $21.13M derived: sum of 3 quarters · filed 2024-03-06 | $25.16M 10-K · filed 2024-03-06 |
| 2021-09-30 | $5.66M 10-Q · filed 2022-11-09 | $11.05M derived: sum of 2 quarters · filed 2022-11-09 | $15.08M 10-Q · filed 2022-11-09 | $20.19M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $5.38M 10-Q · filed 2022-08-10 | $9.41M 10-Q · filed 2022-08-10 | $14.53M derived: sum of 3 quarters · filed 2022-08-10 | $18.40M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.03M 10-Q · filed 2022-05-11 | $9.14M derived: sum of 2 quarters · filed 2022-05-11 | $13.02M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.99M derived: sum of 2 quarters · filed 2022-03-11 | $20.92M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $3.88M 10-Q · filed 2021-11-10 | $15.81M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |